stemmacolore
Search

Clinical Trials

Clinical Trials

The intensive clinical activity of the IOV is carried out by hospital and university doctors who use cutting-edge treatment programs, with the most accredited conventional cancer treatments. This clinical activity is flanked and complemented by an equally lively research activity that leads to the acquisition of new knowledge for the progress of medicine and offers the possibility to use innovative experimental therapies as therapeutic alternatives, in particular, in patients in whom conventional drugs have failed or have been found to be poorly effective.

This last aspect is achieved thanks to the continuous participation of IOV in clinical trials, both national and international, which involve the use of non-commercialized medicines that are not available on the Italian market. In addition, the Institute’s medical specialists promote, design and carry out clinical trials that explore possible new indications of drugs already on the market, in order to test new therapeutic strategies and thus offer further possibilities of cure.

All clinical trials, whether promoted by the pharmaceutical industry or by non-profit organizations, are conducted at IOV according to strict ethical, regulatory and quality standards. Before being started, each trial must be approved by the Ethics Committee for clinical trials, in accordance with the regulations on clinical trials, the dictates of good clinical practice (GCP) and the ethical principles indicated in the Helsinki Declaration.

For the patients included in the experimental protocols, the main care reference is the research nurses, who represent a flagship of the scientific activity of the IOV, one of only two Italian centers to have this professional figure.

The levels of research, diagnosis and treatment conducted in the Institute place the IOV among the most accredited cancer centers nationwide.

Analisi Real World degli esiti di trattamento e delle reazioni avverse riportate dai pazienti con carcinoma prostatico metastatico resistente alla castrazione (mCRPC) trattati con [177Lu]Lu-PSMA-617. Studio Real-Lu177-mCRPC

Stato
Aperto - reclutamento in corso
Codice studio
Real-Lu177-mCRPC
Codice EudraCT
NP
Sponsor/Promotore
IOV
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Analisi in real practice dell’efficacia, sicurezza e delle possibili interazioni di Sacituzumab Govitecan utilizzato in monoterapia per il trattamento di pazienti adulti affetti da carcinoma mammario triplo-negativo metastatico (mTNBC) o TNBC non resecabile che abbiano ricevuto in precedenza almeno due terapie sistemiche, almeno una delle quali per la malattia avanzata (SMARTEST)

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
SMARTEST
Codice EudraCT
NP
Sponsor/Promotore
IOV
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

The ReMM Study: Real-world Evidence on Multiple Myeloma in the Veneto Region

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
ReMM Study
Codice EudraCT
NP
Sponsor/Promotore
Gruppo di Lavoro sui Farmaci Oncoematologici della Regione Veneto
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Analisi in Real Practice delle possibili interazioni degli Antibiotici nei pazienti trattati con Immune Checkpoint Inhibitors (Nivolumab, Avelumab, Pembrolizumab, Cemiplimab, Atezolizumab)

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
NAPCAumab2022
Codice EudraCT
NP
Sponsor/Promotore
IOV
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Search

Status

Last modified: 06/04/2021 15:13

Scroll to Top